A venture capital firm headquartered in the United States focuses on Pre-Seed through Series A opportunities across deeptech, life sciences, and the convergence of technology and healthcare. Backed by family offices and strategic investors across multiple regions, the firm benefits from a network of partners with entrepreneurial and life sciences expertise. The firm typically participates as a co-investor with check sizes ranging from approximately $100K to $1M. In addition to venture investing, the firm collaborates with capital partners on strategic acquisition opportunities and actively supports company formation and incubation. The firm invests globally and assists portfolio companies with expansion into emerging markets across Asia, Africa, and other regions.
The firm takes an opportunistic approach to life sciences and deeptech investing. Key areas of interest include artificial intelligence, health technology, neuroscience, life science tools, and therapeutics. The firm is also open to orphan disease opportunities. Within therapeutics, the firm focuses on companies from the preclinical stage through Phase I clinical development. The firm seeks differentiated technologies with the potential to create meaningful scientific, clinical, or commercial impact.
From a company and management team perspective, the firm does not impose specific requirements regarding leadership composition and does not require board representation as a condition of investment. The firm prefers to support founders through collaborative partnerships and strategic guidance while maintaining flexibility in investment structure and governance.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment